Association of Days Alive and Out of the Hospital After Ventricular Assist Device Implantation With Adverse Events and Quality of Life
JAMA Surgery · 2023
DOI: 10.1001/jamasurg.2022.8127 ↗Kurz gefasst
Fachartikel in der Zeitschrift JAMA Surgery, 2023. Verfasst von Pierre-Emmanuel Noly und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiac Surgery, Michigan Medicine, University of Michigan, Ann Arbor. Hauptthemen laut MEDLINE: Quality of Life, Heart-Assist Devices. Die Arbeit wurde bisher 23-mal zitiert (Crossref) und nennt 29 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NHLBI NIH HHS.
Themen: Patientensicherheit
Abstract (Originalsprache)
Importance There is a need to better assess the cumulative effect on morbidity and mortality in patients undergoing durable left ventricular assist device (LVAD) implantation. This study evaluates a patient-centered performance metric (days alive and out of hospital [DAOH]) for durable LVAD therapy.
Objective
To determine the incidence of percent of DAOH before and after LVAD implantation and (2) explore its association with established quality metrics (death, adverse events [AEs], quality of life). Design, Settings, and Participants This was a retrospective national cohort study of Medicare beneficiaries implanted with a durable continuous-flow LVAD between April 2012 and December 2016. The data were analyzed from December 2021 to May 2022. Follow-up was 100% complete at 1 year. Data from The Society of Thoracic Surgeons Intermacs registry were linked to Medicare claims. Main Outcomes and Measures The number of DAOH 180 days before and 365 days after LVAD implantation and daily patient location (home, index hospital, nonindex hospital, skilled nursing facility, rehabilitation center, hospice) were calculated. Percent of DAOH was indexed to each beneficiary’s pre- (percent DAOH-BF) and postimplantation (percentage of DAOH-AF) follow-up time. The cohort was stratified by terciles of percentage of DAOH-AF.
Results
Among the 3387 patients included (median [IQR] age: 66.3 [57.9-70.9] years), 80.9% were male, 33.6% and 37.1% were Interfaces Patient Profile 2 and 3, respectively, and 61.1% received implants as destination therapy. Median (IQR) percent of DAOH-BF was 88.8% (82.7%-93.8%) and 84.6% (62.1-91.5%) for percent of DAOH-AF. While DAOH-BF was not associated with post-LVAD outcomes, patients in the low tercile of percentage of DAOH-AF had a longer index hospitalization stay (mean, 44 days; 95% CI, 16-77), were less likely to be discharged home (mean. −46.4 days; 95% CI, 44.2-49.1), and spent more time in a skilled nursing facility (mean, 27 days; 95% CI, 24-29), rehabilitation center (mean, 10 days; 95% CI, 8-12), or hospice (mean, 6 days; 95% CI, 4-8). Increasing percentage of DAOH-AF was associated with patient risk, AEs, and indices of HRQoL. Patients experiencing non–LVAD-related AEs had the lowest percentage of DAOH-AF. Conclusions and Relevance Significant variability existed in the percentage of DAOH within a 1-year time horizon and was associated with the cumulative AEs burden. This patient-centered measure may assist clinicians in informing patients about expectations after durable LVAD implantation. Validation of percentage DAOH as a quality metric for LVAD therapy across centers should be explored.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Autor:innen und Institutionen
- Department of Cardiac Surgery, Michigan Medicine, University of Michigan, Ann Arbor.
- Now with the Montreal Heart Institute, Université de Montréal, Quebec, Montréal, Canada.
- Division of Cardiac Surgery, Department of Surgery, Feinberg School of Medicine, Northwestern University, Chicago, Illinois.
- Division of Cardiac Surgery, Yale School of Medicine New Haven, Connecticut.
- Department of Biostatistics, School of Public Health, University of Michigan, Ann Arbor.
- Strategy, Ethics, and Entrepreneurship, Darden School of Business, University of Virginia, Charlottesville.
Förderung
- NHLBI NIH HHS
Zitieren
APA
Noly, P. E., Wu, X., Hou, H., Grady, K. L., Stewart, J. W., Hawkins, R. B., Yang, G., Kim, K. D., Zhang, M., Cabrera, L., Aaronson, K. D., Pagani, F. D., Likosky, D. S., & Michigan Congestive Heart Failure Investigators (2023). Association of Days Alive and Out of the Hospital After Ventricular Assist Device Implantation With Adverse Events and Quality of Life. JAMA Surgery. https://doi.org/10.1001/jamasurg.2022.8127
Vancouver
Noly PE, Wu X, Hou H, Grady KL, Stewart JW, Hawkins RB, et al. Association of Days Alive and Out of the Hospital After Ventricular Assist Device Implantation With Adverse Events and Quality of Life. JAMA Surgery. 2023. doi:10.1001/jamasurg.2022.8127
BibTeX
@article{Noly2023,
author = {Noly, Pierre-Emmanuel and Wu, Xiaoting and Hou, Hechuan and Grady, Kathleen L and Stewart, James W and Hawkins, Robert B and Yang, Guangyu and Kim, K Dennie and Zhang, Min and Cabrera, Lourdes and Aaronson, Keith D and Pagani, Francis D and Likosky, Donald S and Michigan Congestive Heart Failure Investigators, Michigan Congestive Heart Failure Investigators},
title = {Association of Days Alive and Out of the Hospital After Ventricular Assist Device Implantation With Adverse Events and Quality of Life},
journal = {JAMA Surgery},
year = {2023},
doi = {10.1001/jamasurg.2022.8127}
}
EUVIMED